Although IBC, like non-IBC breast cancers, is a heterogeneous disease and can occur as any of the five molecular subtypes, the disease is most commonly either HER2 overexpressing or triple-negative (TN) [13]. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.